A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Novo Nordisk's economic moat is eroding due to increased competition and US drug price pressures, but growth in international ...

Despite boasting a new owner, the Indiana manufacturing plant Novo Nordisk picked up as part of its parent company's Catalent ...

The FDA has identified critical lapses at a production facility operated by Novo Nordisk that is used by several drugmakers, ...

A major U.S. drug manufacturing plant did not properly investigate cat hair, pests, and other problems, the FDA found in a ...

“Semaglutide has been in the US for more than eight years now. In India also, the oral version of this molecule is there for ...

Discover why Hims & Hers Health's subscriber growth, profitability, and telehealth expansion make it a strong buy with a ...

The products reported missing include insulin formulations marketed as Ryzodeg FlexTouch and Fiasp (Penfill and FlexTouch), ...

Novo Nordisk, the maker of the blockbuster diabetes drug Ozempic, is at the center of a brewing legal storm. Once celebrated ...

Whether it’s a cook, a home health aide, or a direct support professional, domestic workers are critical for so many people ...

Novo Nordisk raced to meet demand for its weight-loss drug Wegovy and almost doubled its workforce over five years. Now, the ...

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...